APA

Gari H. H., Gearheart C. M., Fosmire S., DeGala G. D., Fan Z., Torkko K. C., Edgerton S. M., Lucia M. S., Ray R., Thor A. D., Porter C. C. & Lambert J. R. (20171212). Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers. : Oncotarget.

Chicago

Gari Hamid H, Gearheart Christy M, Fosmire Susan, DeGala Gregory D, Fan Zeying, Torkko Kathleen C, Edgerton Susan M, Lucia M Scott, Ray Rahul, Thor Ann D, Porter Christopher C and Lambert James R. 20171212. Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers. : Oncotarget.

Harvard

Gari H. H., Gearheart C. M., Fosmire S., DeGala G. D., Fan Z., Torkko K. C., Edgerton S. M., Lucia M. S., Ray R., Thor A. D., Porter C. C. and Lambert J. R. (20171212). Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers. : Oncotarget.

MLA

Gari Hamid H, Gearheart Christy M, Fosmire Susan, DeGala Gregory D, Fan Zeying, Torkko Kathleen C, Edgerton Susan M, Lucia M Scott, Ray Rahul, Thor Ann D, Porter Christopher C and Lambert James R. Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers. : Oncotarget. 20171212.